Sylvain Fouliard

Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies

Reuben Benjamin, Charlotte Graham, Deborah Yallop et al. · The Lancet · 2020 · 344 citations · Full text

Hematological Malignancy, Cell Therapy, Transplantation +9

UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial

Reuben Benjamin, Nitin Jain, Marcela V. Maus et al. · The Lancet Haematology · 2022 · 121 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Cell Therapy +10

Preliminary Data on Safety, Cellular Kinetics and Anti-Leukemic Activity of UCART19, an Allogeneic Anti-CD19 CAR T-Cell Product, in a Pool of Adult and Pediatric Patients with High-Risk CD19+ Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Reuben Benjamin, Charlotte Graham, Deborah Yallop et al. · Blood · 2018 · 86 citations

Integrated Pharmacokinetic/Pharmacodynamic Model of a Bispecific CD3xCD123 DART Molecule in Nonhuman Primates: Evaluation of Activity and Impact of Immunogenicity

Olivia Campagne, Audrey Delmas, Sylvain Fouliard et al. · Clinical Cancer Research · 2018 · 58 citations · Full text

Pharmacokinetic/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454/PCI-24781) in phase I

Sylvain Fouliard, Renata Robert, Anne Jacquet-Bescond et al. · European Journal of Cancer · 2013 · 33 citations

Administration Schedule, Biochemistry, Medicine +8